HOPE-3 was designed to assess if reducing BP and/or LDL-C would reduce cardiovascular events in study participants at intermediate risk with no prior cardiovascular events.
Commercial wearable devices containing sensors can predict clinical laboratory measurements, including a more precise depiction of resting heart rate, than measurements taken in the clinic.
For older patients with decompensated heart failure, a tailored rehabilitation intervention results in greater improvement in physical function than usual care.
In a guideline issued by the American Heart Association/American Stroke Association and published online May 24 in Stroke, recommendations are presented for prevention of a second stroke.
Patients with the highest levels of EPA had similar rates of major adverse cardiovascular events as patients taking placebo.
Investigators sought to determine whether fluroquinolone use increased the risk for poor clinical outcomes and death in a cohort of patients with aortic dissection or aortic aneurysm.
Bouts of intense exercise can lead to cardiorespiratory fitness and decreased risk for cardiovascular disease in patients with type 2 diabetes.
More than 1 CVD risk factor, compared with one or none, associated with greater disease activity, disability in rheumatoid arthritis.
Findings show 53 percent increased survival among patients using statins before hospitalization.
69.5 percent of adults with CKD eligible for BP lowering according to 2021 KDIGO guideline versus 49.8 percent with 2012 guideline